相关实验视频

Updated: Jun 11, 2025

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

用enasidenib治疗的携带IDH2突变的NSCLC患者的差异化综合征:病例报告

Bhoomika Sukhadia1,2, Dean Tan1, Youjin Oh1

  • 1Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

JTO clinical and research reports
|September 30, 2024
PubMed
概括

异酸脱酶2 (IDH2) 抑制剂,如纳西迪尼布,可以在非小细胞肺癌 (NSCLC) 患者中引起分化综合征. 这种可能致命的炎症反应需要在IDH2向治疗期间仔细监测.

关键词:
案例报告案例报告差异化综合征是什么这是Enasidenib.这是一种IDH2抑制剂.非小细胞肺癌是什么?

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas06:27

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

Published on: May 9, 2025

269

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K